.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

The Changing Landscape in Mantle Cell Lymphoma

EP. 1: Incidence and Clinical Presentation of MCL

January 30th 2020

EP. 2: Biomarkers in Mantle Cell Lymphoma Pathogenesis

January 30th 2020

EP. 3: Clinical Workup for Mantle Cell Lymphoma

January 30th 2020

EP. 4: Prognostic Indicators for Mantle Cell Lymphoma

January 30th 2020

EP. 5: Frontline Therapy for Mantle Cell Lymphoma

January 30th 2020

EP. 6: Changing Treatment Landscape for R/R MCL

January 30th 2020

EP. 7: Recent Approval of Zanubrutinib for R/R MCL

January 30th 2020

EP. 8: Acalabrutinib in R/R MCL

January 30th 2020

EP. 9: Treatment Challenges for R/R MCL

January 30th 2020

EP. 10: Ibrutinib in R/R MCL

January 30th 2020

EP. 11: Recent FDA Approvals in MCL

January 30th 2020

EP. 12: Differences Among BTK Inhibitors for MCL

January 30th 2020

EP. 13: Patient Selection Among FDA Approved BTK Inhibitors

January 30th 2020

EP. 14: Challenges in Treating R/R MCL

January 30th 2020

EP. 15: CAR T-Cell Therapy for MCL

January 30th 2020

EP. 16: Noteworthy Data on MCL: ASH 2019

January 30th 2020

EP. 17: Emerging Treatments in MCL

January 30th 2020

EP. 18: Emerging KTE-X19 CAR T-Cell Therapy for MCL

January 30th 2020

EP. 19: Final Thoughts From ASH 2019 on MCL

January 30th 2020